Text Messaging Intervention Can Up Glycemic Control in T2DM

Share this content:
Text Messaging Intervention Can Up Glycemic Control in T2DM
Text Messaging Intervention Can Up Glycemic Control in T2DM

FRIDAY, June 16, 2017 (HealthDay News) -- For low-income Hispanic patients with poorly controlled type 2 diabetes, a text messaging intervention can improve glycemic control, according to a study published online June 9 in Diabetes Care.

Addie L. Fortmann, Ph.D., from the Scripps Whittier Diabetes Institute in San Diego, and colleagues conducted a randomized trial involving 126 low-income Hispanic participants with poorly controlled type 2 diabetes. Participants were randomized to receive either the Dulce Digital intervention, which included receipt of up to three motivational, education, and/or call-to-action text messages per day over six months, or usual care.

The researchers found that, compared with usual care, there was a significantly greater reduction in hemoglobin A1c (HbA1c) over time in the Dulce Digital group (P = 0.03). There were no statistically significant effects for secondary clinical indicators. The number of blood glucose values that participants texted in was a significant predictor of HbA1c at month six (P < 0.05). High satisfaction and acceptability ratings were seen for the Dulce Digital intervention.

"Use of a simple, low-cost text-messaging program was found to be highly acceptable in this sample of high-risk, Hispanic individuals with type 2 diabetes and resulted in greater improvement in glycemic control compared with usual care," the authors write.

The Investigator-Initiated Study Program of LifeScan provided glucose testing meters and strips for all participants.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths